| NCT03371017 |
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03371017 |
Recruiting |
Hoffmann-La Roche |
2023-01-31 |
| NCT03345485 |
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03345485 |
Active, not recruiting |
Mundipharma-EDO GmbH |
2021-12-31 |
| NCT04441099 |
NBE-002 in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04441099 |
Recruiting |
NBE-Therapeutics AG |
2023-07-31 |
| NCT04434040 |
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC |
https://ClinicalTrials.gov/show/NCT04434040 |
Recruiting |
Dana-Farber Cancer Institute |
2022-04-30 |
| NCT04429542 |
Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04429542 |
Recruiting |
Bicara Therapeutics |
2022-12-31 |
| NCT04177108 |
A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. |
https://ClinicalTrials.gov/show/NCT04177108 |
Recruiting |
Hoffmann-La Roche |
2025-10-10 |
| NCT03971409 |
Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03971409 |
Recruiting |
University of California, San Francisco |
2021-07-30 |
| NCT03829436 |
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03829436 |
Recruiting |
Tempest Therapeutics |
2022-02-18 |
| NCT03818685 |
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease |
https://ClinicalTrials.gov/show/NCT03818685 |
Recruiting |
Centre Leon Berard |
2022-03-01 |
| NCT03719326 |
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies |
https://ClinicalTrials.gov/show/NCT03719326 |
Recruiting |
Arcus Biosciences, Inc. |
2022-02-28 |
| NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03424005 |
Recruiting |
Hoffmann-La Roche |
2023-01-03 |
| NCT03411161 |
S 81694 Plus Paclitaxel in Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT03411161 |
Completed |
Servier |
2020-06-08 |
| NCT03401385 |
First-in-human Study of DS-1062a for Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03401385 |
Recruiting |
Daiichi Sankyo, Inc. |
2022-01-01 |
| NCT03394027 |
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma |
https://ClinicalTrials.gov/show/NCT03394027 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-08-01 |
| NCT03310957 |
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03310957 |
Recruiting |
Seattle Genetics, Inc. |
2020-12-31 |
| NCT03361800 |
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC |
https://ClinicalTrials.gov/show/NCT03361800 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2022-01-15 |
| NCT03337724 |
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03337724 |
Recruiting |
Hoffmann-La Roche |
2021-12-22 |
| NCT03333915 |
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03333915 |
Active, not recruiting |
BeiGene |
2020-02-02 |
| NCT03330847 |
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. |
https://ClinicalTrials.gov/show/NCT03330847 |
Recruiting |
AstraZeneca |
2020-11-30 |
| NCT03316586 |
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03316586 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-05-31 |
| NCT03304756 |
Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen |
https://ClinicalTrials.gov/show/NCT03304756 |
Completed |
Instituto Nacional de Cancer, Brazil |
2012-04-15 |
| NCT03301350 |
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer |
https://ClinicalTrials.gov/show/NCT03301350 |
Active, not recruiting |
University of Wisconsin, Madison |
2022-10-31 |
| NCT03289962 |
A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors |
https://ClinicalTrials.gov/show/NCT03289962 |
Recruiting |
Genentech, Inc. |
2020-09-11 |
| NCT03281954 |
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo |
https://ClinicalTrials.gov/show/NCT03281954 |
Recruiting |
NSABP Foundation Inc |
2023-12-31 |
| NCT03267316 |
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors |
https://ClinicalTrials.gov/show/NCT03267316 |
Recruiting |
Cantargia AB |
2020-07-31 |
| NCT03256344 |
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases |
https://ClinicalTrials.gov/show/NCT03256344 |
Recruiting |
Amgen |
2020-07-13 |
| NCT03254654 |
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03254654 |
Recruiting |
Fudan University |
2019-08-31 |
| NCT03244358 |
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03244358 |
Recruiting |
Sun Yat-sen University |
2022-07-01 |
| NCT03243331 |
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03243331 |
Recruiting |
Indiana University |
2021-01-01 |
| NCT03207867 |
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03207867 |
Recruiting |
Novartis |
2021-10-05 |
| NCT03206203 |
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03206203 |
Recruiting |
Vanderbilt-Ingram Cancer Center |
2021-01-31 |
| NCT03199040 |
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy |
https://ClinicalTrials.gov/show/NCT03199040 |
Recruiting |
Washington University School of Medicine |
2021-09-30 |
| NCT03197935 |
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03197935 |
Active, not recruiting |
Hoffmann-La Roche |
2020-04-02 |
| NCT03197389 |
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. |
https://ClinicalTrials.gov/show/NCT03197389 |
Completed |
Universitaire Ziekenhuizen Leuven |
2020-03-31 |
| NCT03193853 |
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03193853 |
Recruiting |
Baylor Research Institute |
2021-06-09 |
| NCT03184558 |
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC |
https://ClinicalTrials.gov/show/NCT03184558 |
Completed |
BerGenBio ASA |
2018-08-30 |
| NCT03170960 |
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03170960 |
Recruiting |
Exelixis |
2020-12-31 |
| NCT03168880 |
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03168880 |
Active, not recruiting |
Tata Memorial Hospital |
2020-11-30 |
| NCT03167619 |
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) |
https://ClinicalTrials.gov/show/NCT03167619 |
Recruiting |
Duke University |
2021-03-31 |
| NCT03154749 |
TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03154749 |
Recruiting |
Guangdong Provincial People’s Hospital |
2019-12-31 |
| NCT03145961 |
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT03145961 |
Active, not recruiting |
Institute of Cancer Research, United Kingdom |
2021-06-01 |
| NCT03122444 |
Imipramine on Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03122444 |
Recruiting |
The University of Texas Health Science Center at San Antonio |
2020-12-31 |
| NCT03121352 |
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03121352 |
Completed |
Case Comprehensive Cancer Center |
2020-02-06 |
| NCT03109080 |
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT03109080 |
Active, not recruiting |
Institut Curie |
2020-04-30 |
| NCT03106415 |
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03106415 |
Recruiting |
Mayo Clinic |
2021-07-15 |
| NCT03106077 |
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03106077 |
Completed |
M.D. Anderson Cancer Center |
2019-10-01 |
| NCT03101280 |
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03101280 |
Active, not recruiting |
Hoffmann-La Roche |
2020-07-28 |
| NCT03098550 |
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread |
https://ClinicalTrials.gov/show/NCT03098550 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-08-30 |
| NCT03094169 |
AVID100 in Advanced Epithelial Carcinomas |
https://ClinicalTrials.gov/show/NCT03094169 |
Recruiting |
Formation Biologics |
2020-09-01 |
| NCT03092934 |
A Study of AK-01 (LY3295668) in Solid Tumors |
https://ClinicalTrials.gov/show/NCT03092934 |
Active, not recruiting |
Eli Lilly and Company |
2019-12-01 |
| NCT03090165 |
Ribociclib and Bicalutamide in AR+ TNBC |
https://ClinicalTrials.gov/show/NCT03090165 |
Active, not recruiting |
Big Ten Cancer Research Consortium |
2020-09-30 |
| NCT03251378 |
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer |
https://ClinicalTrials.gov/show/NCT03251378 |
Recruiting |
Hutchison Medipharma Limited |
2021-06-15 |
| NCT03057600 |
Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC |
https://ClinicalTrials.gov/show/NCT03057600 |
Completed |
Calithera Biosciences, Inc |
2019-11-25 |
| NCT03055312 |
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03055312 |
Recruiting |
Sun Yat-sen University |
2020-12-31 |
| NCT03036488 |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) |
https://ClinicalTrials.gov/show/NCT03036488 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2025-09-30 |
| NCT03017573 |
Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) |
https://ClinicalTrials.gov/show/NCT03017573 |
Recruiting |
Institut Curie |
2020-12-31 |
| NCT03012230 |
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03012230 |
Recruiting |
Mayo Clinic |
2021-03-15 |
| NCT03012100 |
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03012100 |
Recruiting |
Academic and Community Cancer Research United |
2021-07-31 |
| NCT03004183 |
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC |
https://ClinicalTrials.gov/show/NCT03004183 |
Recruiting |
The Methodist Hospital System |
2022-05-31 |
| NCT03002103 |
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03002103 |
Recruiting |
SynCore Biotechnology Co., Ltd. |
2023-03-31 |
| NCT02996825 |
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02996825 |
Recruiting |
City of Hope Medical Center |
2023-02-22 |
| NCT02993094 |
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02993094 |
Recruiting |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2020-09-30 |
| NCT02984683 |
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02984683 |
Completed |
Sanofi |
2018-08-13 |
| NCT02981303 |
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02981303 |
Active, not recruiting |
Biothera |
2019-04-30 |
| NCT02978716 |
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) |
https://ClinicalTrials.gov/show/NCT02978716 |
Active, not recruiting |
G1 Therapeutics, Inc. |
2018-07-30 |
| NCT02978495 |
Neoadjuvant Carboplatin in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02978495 |
Recruiting |
Barretos Cancer Hospital |
2019-12-31 |
| NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02977468 |
Recruiting |
Columbia University |
2020-12-31 |
| NCT02971761 |
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02971761 |
Active, not recruiting |
City of Hope Medical Center |
2020-11-03 |
| NCT02950259 |
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) |
https://ClinicalTrials.gov/show/NCT02950259 |
Active, not recruiting |
Providence Health & Services |
2018-04-26 |
| NCT02938442 |
Vaccination of Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT02938442 |
Recruiting |
University of Arkansas |
2021-11-30 |
| NCT02936102 |
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. |
https://ClinicalTrials.gov/show/NCT02936102 |
Active, not recruiting |
Novartis |
2021-06-01 |
| NCT02926690 |
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02926690 |
Recruiting |
OncoTherapy Science, Inc. |
2020-12-31 |
| NCT02926196 |
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab |
https://ClinicalTrials.gov/show/NCT02926196 |
Recruiting |
Istituto Oncologico Veneto IRCCS |
2021-06-30 |
| NCT02900664 |
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) |
https://ClinicalTrials.gov/show/NCT02900664 |
Active, not recruiting |
Novartis |
2020-08-21 |
| NCT02898207 |
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02898207 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-01 |
| NCT02897050 |
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02897050 |
Recruiting |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2020-12-31 |
| NCT02890069 |
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat |
https://ClinicalTrials.gov/show/NCT02890069 |
Recruiting |
Novartis |
2021-05-28 |
| NCT02883062 |
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02883062 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-07-01 |
| NCT02834403 |
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT02834403 |
Recruiting |
The Methodist Hospital System |
2020-12-31 |
| NCT02826434 |
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02826434 |
Active, not recruiting |
Massachusetts General Hospital |
2021-02-28 |
| NCT02807844 |
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT02807844 |
Active, not recruiting |
Novartis |
2020-04-28 |
| NCT02806258 |
Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone |
https://ClinicalTrials.gov/show/NCT02806258 |
Recruiting |
University Hospital, Grenoble |
2021-03-31 |
| NCT02789332 |
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency |
https://ClinicalTrials.gov/show/NCT02789332 |
Completed |
German Breast Group |
2019-02-28 |
| NCT02788981 |
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02788981 |
Recruiting |
University of Chicago |
2022-02-28 |
| NCT02755272 |
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02755272 |
Recruiting |
Fox Chase Cancer Center |
2021-10-31 |
| NCT02750358 |
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02750358 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT02744053 |
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02744053 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT02734290 |
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer |
https://ClinicalTrials.gov/show/NCT02734290 |
Active, not recruiting |
Providence Health & Services |
2021-05-31 |
| NCT02730130 |
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT02730130 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2017-09-26 |
| NCT02723877 |
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) |
https://ClinicalTrials.gov/show/NCT02723877 |
Completed |
PIQUR Therapeutics AG |
2018-10-03 |
| NCT02719691 |
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02719691 |
Recruiting |
University of Colorado, Denver |
2021-02-28 |
| NCT02689427 |
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02689427 |
Recruiting |
M.D. Anderson Cancer Center |
2020-09-30 |
| NCT02688803 |
Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) |
https://ClinicalTrials.gov/show/NCT02688803 |
Completed |
Ottawa Hospital Research Institute |
2017-10-31 |
| NCT02670109 |
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT02670109 |
Recruiting |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2020-11-30 |
| NCT02658214 |
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02658214 |
Completed |
AstraZeneca |
2019-11-14 |
| NCT02657889 |
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02657889 |
Active, not recruiting |
Tesaro, Inc. |
2018-05-31 |
| NCT02644369 |
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02644369 |
Active, not recruiting |
University Health Network, Toronto |
2021-01-31 |
| NCT02641847 |
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature |
https://ClinicalTrials.gov/show/NCT02641847 |
Recruiting |
Fudan University |
2021-06-30 |
| NCT02637531 |
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 |
https://ClinicalTrials.gov/show/NCT02637531 |
Active, not recruiting |
Infinity Pharmaceuticals, Inc. |
2020-12-31 |
| NCT02624700 |
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02624700 |
Active, not recruiting |
Virginia Commonwealth University |
2019-07-10 |
| NCT02622074 |
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173) |
https://ClinicalTrials.gov/show/NCT02622074 |
Completed |
Merck Sharp & Dohme Corp. |
2018-05-31 |
| NCT02615457 |
Huaier Granule in Treating Women With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02615457 |
Recruiting |
Shandong University |
2025-10-31 |
| NCT02595138 |
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02595138 |
Active, not recruiting |
Chinese Academy of Medical Sciences |
2018-10-31 |
| NCT02593227 |
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02593227 |
Active, not recruiting |
Marker Therapeutics, Inc. |
2021-12-31 |
| NCT02574455 |
ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02574455 |
Active, not recruiting |
Immunomedics, Inc. |
2020-06-30 |
| NCT04432857 |
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04432857 |
Recruiting |
Adlai Nortye Biopharma Co., Ltd. |
2022-12-31 |
| NCT03125902 |
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT03125902 |
Active, not recruiting |
Hoffmann-La Roche |
2019-11-15 |
| NCT02632448 |
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer |
https://ClinicalTrials.gov/show/NCT02632448 |
Recruiting |
Esperas Pharma Inc. |
2020-03-27 |
| NCT02530489 |
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02530489 |
Recruiting |
M.D. Anderson Cancer Center |
2021-02-28 |
| NCT03801369 |
Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03801369 |
Recruiting |
OHSU Knight Cancer Institute |
2020-12-31 |
| NCT02546934 |
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT02546934 |
Active, not recruiting |
Fudan University |
2020-04-30 |
| NCT02531932 |
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02531932 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2020-12-31 |
| NCT02531425 |
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC |
https://ClinicalTrials.gov/show/NCT02531425 |
Completed |
OncoSec Medical Incorporated |
2018-07-31 |
| NCT02527434 |
Study of Tremelimumab in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02527434 |
Active, not recruiting |
AstraZeneca |
2018-02-17 |
| NCT02521363 |
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02521363 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-07-31 |
| NCT02513472 |
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) |
https://ClinicalTrials.gov/show/NCT02513472 |
Completed |
Eisai Inc. |
2019-07-31 |
| NCT02489448 |
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02489448 |
Recruiting |
Yale University |
2020-10-31 |
| NCT03387085 |
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. |
https://ClinicalTrials.gov/show/NCT03387085 |
Active, not recruiting |
NantKwest, Inc. |
2019-12-31 |
| NCT02474173 |
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02474173 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02455141 |
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02455141 |
Recruiting |
Shanghai Jiao Tong University School of Medicine |
2021-06-30 |
| NCT02447003 |
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) |
https://ClinicalTrials.gov/show/NCT02447003 |
Completed |
Merck Sharp & Dohme Corp. |
2020-01-31 |
| NCT02441933 |
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) |
https://ClinicalTrials.gov/show/NCT02441933 |
Recruiting |
Yonsei University |
2023-03-31 |
| NCT02435680 |
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT02435680 |
Active, not recruiting |
Novartis |
2020-07-20 |
| NCT02427581 |
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT02427581 |
Recruiting |
Washington University School of Medicine |
2021-08-31 |
| NCT02425891 |
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) |
https://ClinicalTrials.gov/show/NCT02425891 |
Active, not recruiting |
Hoffmann-La Roche |
2020-04-14 |
| NCT02422498 |
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy |
https://ClinicalTrials.gov/show/NCT02422498 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT02413320 |
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02413320 |
Completed |
University of Kansas Medical Center |
2019-02-01 |
| NCT02411656 |
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy |
https://ClinicalTrials.gov/show/NCT02411656 |
Recruiting |
M.D. Anderson Cancer Center |
2020-06-01 |
| NCT02402764 |
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT02402764 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2016-03-10 |
| NCT02401347 |
Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors |
https://ClinicalTrials.gov/show/NCT02401347 |
Recruiting |
Stanford University |
2021-08-31 |
| NCT02375958 |
PCA062 in pCAD-positive Tumors. |
https://ClinicalTrials.gov/show/NCT02375958 |
Completed |
Novartis |
2018-07-17 |
| NCT02370238 |
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02370238 |
Active, not recruiting |
Dompé Farmaceutici S.p.A |
2018-12-31 |
| NCT02352025 |
S-equol in Women With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02352025 |
Active, not recruiting |
The University of Texas Health Science Center at San Antonio |
2019-04-10 |
| NCT02341911 |
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT02341911 |
Recruiting |
Fudan University |
2019-12-31 |
| NCT02322814 |
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread |
https://ClinicalTrials.gov/show/NCT02322814 |
Active, not recruiting |
Hoffmann-La Roche |
2018-08-10 |
| NCT02316457 |
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID |
https://ClinicalTrials.gov/show/NCT02316457 |
Active, not recruiting |
Biontech SE |
2020-06-30 |
| NCT02315196 |
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer |
https://ClinicalTrials.gov/show/NCT02315196 |
Recruiting |
Rutgers, The State University of New Jersey |
2022-07-31 |
| NCT02307240 |
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors |
https://ClinicalTrials.gov/show/NCT02307240 |
Completed |
Curis, Inc. |
2019-05-31 |
| NCT02301988 |
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02301988 |
Completed |
Genentech, Inc. |
2017-08-02 |
| NCT02266420 |
Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm |
https://ClinicalTrials.gov/show/NCT02266420 |
Active, not recruiting |
Institut Claudius Regaud |
2023-06-30 |
| NCT02259114 |
A Dose-Finding Study of MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) |
https://ClinicalTrials.gov/show/NCT02259114 |
Completed |
Oncoethix GmbH |
2017-03-03 |
| NCT02225470 |
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes |
https://ClinicalTrials.gov/show/NCT02225470 |
Completed |
Eisai Inc. |
2017-09-29 |
| NCT02203513 |
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer |
https://ClinicalTrials.gov/show/NCT02203513 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-06-01 |
| NCT02183805 |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02183805 |
Recruiting |
Sun Yat-sen University |
2022-12-31 |
| NCT02178722 |
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers |
https://ClinicalTrials.gov/show/NCT02178722 |
Active, not recruiting |
Incyte Corporation |
2018-11-26 |
| NCT02158507 |
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02158507 |
Active, not recruiting |
University of Alabama at Birmingham |
2020-12-31 |
| NCT02130700 |
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer |
https://ClinicalTrials.gov/show/NCT02130700 |
Completed |
Innocrin Pharmaceutical |
2017-09-30 |
| NCT02124902 |
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity |
https://ClinicalTrials.gov/show/NCT02124902 |
Recruiting |
Washington University School of Medicine |
2021-03-31 |
| NCT02101385 |
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02101385 |
Active, not recruiting |
Hoosier Cancer Research Network |
2021-06-30 |
| NCT02071862 |
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors |
https://ClinicalTrials.gov/show/NCT02071862 |
Completed |
Calithera Biosciences, Inc |
2019-03-31 |
| NCT01307891 |
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01307891 |
Completed |
University of Alabama at Birmingham |
2016-06-30 |
| NCT01306032 |
Phase II ABT-888 With Cyclophosphamide |
https://ClinicalTrials.gov/show/NCT01306032 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-12-31 |
| NCT01287624 |
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT01287624 |
Completed |
Fudan University |
2014-03-31 |
| NCT02032277 |
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02032277 |
Active, not recruiting |
AbbVie |
2016-03-18 |
| NCT03358017 |
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03358017 |
Recruiting |
Mario Negri Institute for Pharmacological Research |
2020-07-25 |
| NCT03356860 |
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. |
https://ClinicalTrials.gov/show/NCT03356860 |
Recruiting |
Grand Hôpital de Charleroi |
2021-04-30 |
| NCT02768701 |
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02768701 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2023-03-15 |
| NCT02348320 |
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT02348320 |
Completed |
Washington University School of Medicine |
2020-03-12 |
| NCT02014337 |
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors |
https://ClinicalTrials.gov/show/NCT02014337 |
Completed |
Corcept Therapeutics |
2017-12-31 |
| NCT02001519 |
Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT02001519 |
Completed |
Asan Medical Center |
2014-02-28 |
| NCT01997333 |
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01997333 |
Completed |
Celldex Therapeutics |
2017-11-30 |
| NCT01986426 |
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab |
https://ClinicalTrials.gov/show/NCT01986426 |
Completed |
Lytix Biopharma AS |
2018-04-30 |
| NCT01982448 |
Cisplatin vs Paclitaxel for Triple Neg |
https://ClinicalTrials.gov/show/NCT01982448 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2019-04-30 |
| NCT01969032 |
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01969032 |
Completed |
Russian Academy of Medical Sciences |
2014-05-31 |
| NCT01964924 |
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01964924 |
Completed |
National Cancer Institute (NCI) |
2017-01-20 |
| NCT01931163 |
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer |
https://ClinicalTrials.gov/show/NCT01931163 |
Completed |
The Methodist Hospital System |
2019-01-31 |
| NCT01920061 |
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) |
https://ClinicalTrials.gov/show/NCT01920061 |
Recruiting |
Pfizer |
2020-01-10 |
| NCT01898117 |
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01898117 |
Recruiting |
The Netherlands Cancer Institute |
2020-12-31 |
| NCT01889238 |
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01889238 |
Active, not recruiting |
Pfizer |
2015-03-01 |
| NCT01884285 |
AZD8186 First Time In Patient Ascending Dose Study |
https://ClinicalTrials.gov/show/NCT01884285 |
Completed |
AstraZeneca |
2019-03-31 |
| NCT01881230 |
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) |
https://ClinicalTrials.gov/show/NCT01881230 |
Completed |
Celgene |
2016-10-28 |
| NCT01837602 |
cMet CAR RNA T Cells Targeting Breast Cancer |
https://ClinicalTrials.gov/show/NCT01837602 |
Completed |
University of Pennsylvania |
2018-08-13 |
| NCT01818063 |
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer |
https://ClinicalTrials.gov/show/NCT01818063 |
Completed |
Thomas Jefferson University |
2015-03-01 |
| NCT01815242 |
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01815242 |
Active, not recruiting |
West German Study Group |
2015-03-31 |
| NCT01805076 |
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer |
https://ClinicalTrials.gov/show/NCT01805076 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2025-02-28 |
| NCT01770353 |
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment |
https://ClinicalTrials.gov/show/NCT01770353 |
Completed |
Ipsen |
2018-10-02 |
| NCT01677455 |
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer |
https://ClinicalTrials.gov/show/NCT01677455 |
Completed |
Synta Pharmaceuticals Corp. |
2015-04-30 |
| NCT01676753 |
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer |
https://ClinicalTrials.gov/show/NCT01676753 |
Active, not recruiting |
University of California, San Francisco |
2020-06-01 |
| NCT01674842 |
Cisplatin + RT for Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01674842 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2018-08-31 |
| NCT01672671 |
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy |
https://ClinicalTrials.gov/show/NCT01672671 |
Completed |
Russian Academy of Medical Sciences |
2015-06-30 |
| NCT01650506 |
Study of Erlotinib and Metformin in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01650506 |
Completed |
Columbia University |
2016-06-30 |
| NCT01639248 |
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC |
https://ClinicalTrials.gov/show/NCT01639248 |
Completed |
CASI Pharmaceuticals, Inc. |
2017-06-30 |
| NCT01631552 |
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers |
https://ClinicalTrials.gov/show/NCT01631552 |
Active, not recruiting |
Immunomedics, Inc. |
2020-06-30 |
| NCT01624441 |
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01624441 |
Completed |
National Cancer Institute (NCI) |
2013-09-10 |
| NCT01623349 |
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01623349 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2019-05-31 |
| NCT01618136 |
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT01618136 |
Completed |
Eisai Inc. |
2015-07-31 |
| NCT01617668 |
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01617668 |
Completed |
Novartis |
2014-09-30 |
| NCT01525966 |
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01525966 |
Active, not recruiting |
City of Hope Medical Center |
2023-02-28 |
| NCT01520389 |
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment |
https://ClinicalTrials.gov/show/NCT01520389 |
Completed |
Merrimack Pharmaceuticals |
2015-12-31 |
| NCT01467310 |
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
https://ClinicalTrials.gov/show/NCT01467310 |
Completed |
UNC Lineberger Comprehensive Cancer Center |
2016-04-30 |
| NCT01451632 |
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT01451632 |
Completed |
Merrimack Pharmaceuticals |
2013-11-30 |
| NCT01421472 |
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01421472 |
Completed |
Merrimack Pharmaceuticals |
2013-12-31 |
| NCT01391143 |
Safety Study of MGA271 in Refractory Cancer |
https://ClinicalTrials.gov/show/NCT01391143 |
Completed |
MacroGenics |
2019-04-18 |
| NCT01372579 |
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT01372579 |
Active, not recruiting |
Northwestern University |
2020-06-30 |
| NCT01351103 |
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands |
https://ClinicalTrials.gov/show/NCT01351103 |
Recruiting |
Novartis |
2022-03-25 |
| NCT04437160 |
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT04437160 |
Recruiting |
Chinese Academy of Medical Sciences |
2026-01-31 |
| NCT04418154 |
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT04418154 |
Recruiting |
Fudan University |
2021-06-15 |
| NCT03599453 |
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03599453 |
Recruiting |
Roswell Park Cancer Institute |
2021-06-06 |
| NCT04403529 |
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04403529 |
Recruiting |
Fudan University |
2024-05-31 |
| NCT04395989 |
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. |
https://ClinicalTrials.gov/show/NCT04395989 |
Recruiting |
Fudan University |
2022-11-15 |
| NCT04344795 |
Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors |
https://ClinicalTrials.gov/show/NCT04344795 |
Recruiting |
Tempest Therapeutics |
2021-08-31 |
| NCT04335669 |
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC |
https://ClinicalTrials.gov/show/NCT04335669 |
Recruiting |
Lund University Hospital |
2023-06-25 |
| NCT04332653 |
NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04332653 |
Recruiting |
NeoImmuneTech |
2022-06-30 |
| NCT04301011 |
Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors |
https://ClinicalTrials.gov/show/NCT04301011 |
Recruiting |
Turnstone Biologics, Corp. |
2022-08-20 |
| NCT04297267 |
A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT04297267 |
Recruiting |
Fudan University |
2022-12-31 |
| NCT04296175 |
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) |
https://ClinicalTrials.gov/show/NCT04296175 |
Recruiting |
Fudan University |
2024-06-30 |
| NCT04251533 |
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation |
https://ClinicalTrials.gov/show/NCT04251533 |
Recruiting |
Novartis |
2023-06-19 |
| NCT04249167 |
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04249167 |
Recruiting |
Mayo Clinic |
2020-12-31 |
| NCT04248998 |
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04248998 |
Recruiting |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2022-12-31 |
| NCT04234113 |
Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04234113 |
Recruiting |
Sotio a.s. |
2022-03-31 |
| NCT04224922 |
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04224922 |
Completed |
AZ-VUB |
2016-07-31 |
| NCT04216472 |
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations |
https://ClinicalTrials.gov/show/NCT04216472 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT04191135 |
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) |
https://ClinicalTrials.gov/show/NCT04191135 |
Recruiting |
Merck Sharp & Dohme Corp. |
2026-01-26 |
| NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
https://ClinicalTrials.gov/show/NCT04180371 |
Recruiting |
Bicycle Tx Limited |
2022-12-31 |
| NCT04176848 |
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04176848 |
Recruiting |
Canadian Cancer Trials Group |
2022-05-30 |
| NCT04159818 |
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients |
https://ClinicalTrials.gov/show/NCT04159818 |
Recruiting |
The Netherlands Cancer Institute |
2022-12-15 |
| NCT04159142 |
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04159142 |
Recruiting |
Hebei Medical University Fourth Hospital |
2022-06-20 |
| NCT04158336 |
A Study of ZN-c3 in Participants With Solid Tumors |
https://ClinicalTrials.gov/show/NCT04158336 |
Recruiting |
K-Group Beta |
2023-05-31 |
| NCT04157517 |
A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study |
https://ClinicalTrials.gov/show/NCT04157517 |
Recruiting |
Takeda |
2023-02-15 |
| NCT04152499 |
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
https://ClinicalTrials.gov/show/NCT04152499 |
Recruiting |
Klus Pharma Inc. |
2021-12-31 |
| NCT04148911 |
A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04148911 |
Recruiting |
Hoffmann-La Roche |
2024-05-21 |
| NCT04142931 |
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Removal of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04142931 |
Recruiting |
Sheba Medical Center |
2021-12-30 |
| NCT04138719 |
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer |
https://ClinicalTrials.gov/show/NCT04138719 |
Recruiting |
Hebei Medical University Fourth Hospital |
2020-10-20 |
| NCT04134884 |
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT04134884 |
Recruiting |
Indiana University |
2020-12-31 |
| NCT04129996 |
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) |
https://ClinicalTrials.gov/show/NCT04129996 |
Recruiting |
Fudan University |
2021-01-01 |
| NCT04115306 |
Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04115306 |
Recruiting |
Phoenix Molecular Designs |
2022-09-30 |
| NCT04111510 |
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04111510 |
Recruiting |
Yale University |
2022-01-31 |
| NCT04105582 |
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells |
https://ClinicalTrials.gov/show/NCT04105582 |
Recruiting |
Universidad Nacional de Colombia |
2020-08-01 |
| NCT04085276 |
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
https://ClinicalTrials.gov/show/NCT04085276 |
Recruiting |
Shanghai Junshi Bioscience Co., Ltd. |
2022-02-28 |
| NCT04083963 |
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04083963 |
Recruiting |
University of Illinois at Chicago |
2022-02-05 |
| NCT04081389 |
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04081389 |
Recruiting |
Roswell Park Cancer Institute |
2022-07-30 |
| NCT04067102 |
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC |
https://ClinicalTrials.gov/show/NCT04067102 |
Recruiting |
Hebei Medical University Fourth Hospital |
2021-05-31 |
| NCT04060342 |
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT04060342 |
Recruiting |
Gossamer Bio Inc. |
2023-03-31 |
| NCT04032080 |
Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib |
https://ClinicalTrials.gov/show/NCT04032080 |
Recruiting |
Baylor Research Institute |
2021-06-30 |
| NCT04031703 |
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) |
https://ClinicalTrials.gov/show/NCT04031703 |
Completed |
Fudan University |
2016-04-20 |
| NCT04030507 |
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer |
https://ClinicalTrials.gov/show/NCT04030507 |
Recruiting |
Dana-Farber Cancer Institute |
2022-07-01 |
| NCT04025216 |
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers |
https://ClinicalTrials.gov/show/NCT04025216 |
Recruiting |
Tmunity Therapeutics |
2022-12-31 |
| NCT04024800 |
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT04024800 |
Recruiting |
Antigen Express, Inc |
2023-06-30 |
| NCT04004910 |
Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT04004910 |
Recruiting |
Immunicom Inc |
2020-12-31 |
| NCT03997123 |
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC |
https://ClinicalTrials.gov/show/NCT03997123 |
Recruiting |
AstraZeneca |
2022-06-10 |
| NCT03992131 |
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) |
https://ClinicalTrials.gov/show/NCT03992131 |
Recruiting |
Clovis Oncology, Inc. |
2023-10-31 |
| NCT03982173 |
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03982173 |
Active, not recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2021-04-30 |
| NCT03961698 |
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) |
https://ClinicalTrials.gov/show/NCT03961698 |
Recruiting |
Infinity Pharmaceuticals, Inc. |
2022-08-01 |
| NCT03945721 |
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT03945721 |
Recruiting |
Massachusetts General Hospital |
2021-05-31 |
| NCT03945604 |
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC |
https://ClinicalTrials.gov/show/NCT03945604 |
Recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2021-04-20 |
| NCT03917381 |
GEN1046 Safety Trial in Patients With Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT03917381 |
Recruiting |
Genmab |
2021-10-31 |
| NCT03901469 |
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03901469 |
Recruiting |
Zenith Epigenetics |
2020-09-30 |
| NCT03893955 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03893955 |
Recruiting |
AbbVie |
2023-05-11 |
| NCT03891953 |
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. |
https://ClinicalTrials.gov/show/NCT03891953 |
Recruiting |
Novartis |
2022-11-28 |
| NCT03881605 |
MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC |
https://ClinicalTrials.gov/show/NCT03881605 |
Recruiting |
Sunnybrook Health Sciences Centre |
2021-06-30 |
| NCT03876886 |
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency |
https://ClinicalTrials.gov/show/NCT03876886 |
Recruiting |
Chinese Academy of Medical Sciences |
2024-02-29 |
| NCT03875313 |
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03875313 |
Recruiting |
Calithera Biosciences, Inc |
2020-12-31 |
| NCT03872791 |
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03872791 |
Recruiting |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2020-09-15 |
| NCT03872388 |
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT03872388 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT03861403 |
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03861403 |
Active, not recruiting |
Leap Therapeutics, Inc. |
2021-06-30 |
| NCT03855358 |
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) |
https://ClinicalTrials.gov/show/NCT03855358 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-06-30 |
| NCT03853707 |
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03853707 |
Recruiting |
City of Hope Medical Center |
2022-06-21 |
| NCT03838367 |
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC |
https://ClinicalTrials.gov/show/NCT03838367 |
Recruiting |
CytoDyn, Inc. |
2020-03-31 |
| NCT03829501 |
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer |
https://ClinicalTrials.gov/show/NCT03829501 |
Recruiting |
Kymab Limited |
2023-05-31 |
| NCT03812393 |
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast |
https://ClinicalTrials.gov/show/NCT03812393 |
Recruiting |
West Cancer Center |
2020-10-15 |
| NCT03808662 |
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung |
https://ClinicalTrials.gov/show/NCT03808662 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-01-31 |
| NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
https://ClinicalTrials.gov/show/NCT03808337 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-01-31 |
| NCT03805399 |
FUSCC Refractory TNBC Umbrella (FUTURE) |
https://ClinicalTrials.gov/show/NCT03805399 |
Recruiting |
Fudan University |
2022-01-01 |
| NCT03800836 |
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03800836 |
Recruiting |
Hoffmann-La Roche |
2022-10-29 |
| NCT03799679 |
Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03799679 |
Recruiting |
Fudan University |
2019-11-30 |
| NCT03775928 |
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03775928 |
Recruiting |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2020-12-01 |
| NCT03775850 |
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors |
https://ClinicalTrials.gov/show/NCT03775850 |
Recruiting |
Evelo Biosciences, Inc. |
2020-12-19 |
| NCT03761914 |
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03761914 |
Recruiting |
Sellas Life Sciences Group |
2020-12-31 |
| NCT03756298 |
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03756298 |
Recruiting |
National Cancer Center, Korea |
2024-01-31 |
| NCT03752723 |
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) |
https://ClinicalTrials.gov/show/NCT03752723 |
Recruiting |
Genexine, Inc. |
2021-07-31 |
| NCT03750240 |
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy |
https://ClinicalTrials.gov/show/NCT03750240 |
Recruiting |
NYU Langone Health |
2020-08-31 |
| NCT03742349 |
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). |
https://ClinicalTrials.gov/show/NCT03742349 |
Recruiting |
Novartis |
2022-01-17 |
| NCT03742102 |
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03742102 |
Recruiting |
AstraZeneca |
2020-12-30 |
| NCT03740893 |
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03740893 |
Recruiting |
Institute of Cancer Research, United Kingdom |
2023-03-31 |
| NCT03739931 |
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03739931 |
Recruiting |
ModernaTX, Inc. |
2020-06-30 |
| NCT03735082 |
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03735082 |
Recruiting |
Chinese Academy of Medical Sciences |
2020-06-01 |
| NCT03720431 |
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03720431 |
Active, not recruiting |
PharmAbcine |
2020-04-30 |
| NCT03709446 |
Leflunomide in Previously Treated Metastatic Triple Negative Cancers |
https://ClinicalTrials.gov/show/NCT03709446 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2021-10-20 |
| NCT03674827 |
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC |
https://ClinicalTrials.gov/show/NCT03674827 |
Recruiting |
Pfizer |
2023-12-25 |
| NCT03674242 |
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) |
https://ClinicalTrials.gov/show/NCT03674242 |
Recruiting |
ERYtech Pharma |
2020-12-31 |
| NCT03671044 |
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT03671044 |
Recruiting |
Jina Pharmaceuticals Inc. |
2022-03-31 |
| NCT03667716 |
COM701 in Subjects With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03667716 |
Recruiting |
Compugen Ltd |
2021-06-30 |
| NCT03665285 |
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03665285 |
Recruiting |
NextCure, Inc. |
2021-05-01 |
| NCT03654547 |
Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03654547 |
Recruiting |
TransThera Biosciences Co., Ltd |
2020-03-31 |
| NCT03652077 |
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03652077 |
Recruiting |
Incyte Corporation |
2021-01-31 |
| NCT03650738 |
This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment |
https://ClinicalTrials.gov/show/NCT03650738 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2019-12-30 |
| NCT03639948 |
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03639948 |
Recruiting |
University of Kansas Medical Center |
2021-11-30 |
| NCT03634150 |
Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03634150 |
Recruiting |
Immune System Key Ltd |
2020-06-30 |
| NCT03616886 |
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC |
https://ClinicalTrials.gov/show/NCT03616886 |
Recruiting |
Jules Bordet Institute |
2022-09-30 |
| NCT03609671 |
Emotions Immunology and Breast Cancer |
https://ClinicalTrials.gov/show/NCT03609671 |
Completed |
The Methodist Hospital System |
2019-03-18 |
| NCT03579472 |
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03579472 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT03577743 |
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03577743 |
Recruiting |
Assiut University |
2020-05-31 |
| NCT03576131 |
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT03576131 |
Recruiting |
Genmab |
2021-12-31 |
| NCT03567720 |
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC |
https://ClinicalTrials.gov/show/NCT03567720 |
Active, not recruiting |
OncoSec Medical Incorporated |
2023-07-31 |
| NCT03562637 |
Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. |
https://ClinicalTrials.gov/show/NCT03562637 |
Recruiting |
OBI Pharma, Inc |
2025-11-30 |
| NCT03549000 |
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. |
https://ClinicalTrials.gov/show/NCT03549000 |
Recruiting |
Novartis |
2022-01-24 |
| NCT03542175 |
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy |
https://ClinicalTrials.gov/show/NCT03542175 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT03538028 |
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03538028 |
Recruiting |
Incyte Corporation |
2020-09-24 |
| NCT03519178 |
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy |
https://ClinicalTrials.gov/show/NCT03519178 |
Recruiting |
Pfizer |
2023-03-19 |
| NCT03504488 |
CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03504488 |
Recruiting |
BioAtla, LLC |
2020-05-13 |
| NCT03499899 |
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03499899 |
Active, not recruiting |
Novartis |
2020-02-27 |
| NCT03498716 |
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03498716 |
Recruiting |
Hoffmann-La Roche |
2022-01-15 |
| NCT03487666 |
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease |
https://ClinicalTrials.gov/show/NCT03487666 |
Recruiting |
Georgetown University |
2021-12-31 |
| NCT03483012 |
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis |
https://ClinicalTrials.gov/show/NCT03483012 |
Recruiting |
Dana-Farber Cancer Institute |
2021-09-30 |
| NCT03464942 |
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03464942 |
Recruiting |
Peter MacCallum Cancer Centre, Australia |
2021-10-31 |
| NCT03457779 |
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03457779 |
Active, not recruiting |
Baylor Research Institute |
2020-04-08 |
| NCT03454451 |
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03454451 |
Recruiting |
Corvus Pharmaceuticals, Inc. |
2022-03-31 |
| NCT03435640 |
A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies |
https://ClinicalTrials.gov/show/NCT03435640 |
Recruiting |
Nektar Therapeutics |
2021-09-30 |
| NCT03414684 |
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03414684 |
Recruiting |
Dana-Farber Cancer Institute |
2021-06-30 |
| NCT01238952 |
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01238952 |
Completed |
Nippon Kayaku Co., Ltd. |
2010-11-30 |
| NCT01216111 |
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) |
https://ClinicalTrials.gov/show/NCT01216111 |
Completed |
Fudan University |
2016-04-20 |
| NCT01204125 |
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT01204125 |
Completed |
Sanofi |
2012-10-31 |
| NCT01186991 |
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01186991 |
Completed |
Genentech, Inc. |
2016-03-31 |
| NCT01176669 |
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT01176669 |
Completed |
Fudan University |
2014-06-30 |
| NCT01173497 |
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis |
https://ClinicalTrials.gov/show/NCT01173497 |
Completed |
Sanofi |
2012-10-31 |
| NCT01150513 |
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01150513 |
Completed |
Chinese Academy of Medical Sciences |
2016-01-31 |
| NCT01116648 |
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01116648 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01111825 |
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01111825 |
Completed |
Puma Biotechnology, Inc. |
2016-07-31 |
| NCT01104259 |
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01104259 |
Completed |
University of Washington |
2015-02-28 |
| NCT01097642 |
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT01097642 |
Completed |
The Methodist Hospital System |
2019-12-31 |
| NCT01094184 |
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01094184 |
Completed |
Hoffmann-La Roche |
2015-12-31 |
| NCT01091454 |
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01091454 |
Completed |
Alliance for Clinical Trials in Oncology |
2012-06-30 |
| NCT01074970 |
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations |
https://ClinicalTrials.gov/show/NCT01074970 |
Completed |
Hoosier Cancer Research Network |
2018-12-15 |
| NCT01045304 |
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT01045304 |
Completed |
Sanofi |
2011-03-31 |
| NCT00998036 |
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors |
https://ClinicalTrials.gov/show/NCT00998036 |
Completed |
Columbia University |
2012-06-30 |
| NCT00986609 |
MUC1 Vaccine for Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT00986609 |
Completed |
Case Comprehensive Cancer Center |
2013-08-29 |
| NCT00951054 |
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT00951054 |
Completed |
Nippon Kayaku Co., Ltd. |
2014-12-31 |
| NCT00887575 |
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT00887575 |
Completed |
SCRI Development Innovations, LLC |
2013-07-31 |
| NCT03911973 |
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers |
https://ClinicalTrials.gov/show/NCT03911973 |
Recruiting |
Big Ten Cancer Research Consortium |
2021-05-31 |
| NCT03621982 |
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03621982 |
Recruiting |
ADC Therapeutics S.A. |
2021-03-31 |
| NCT03362060 |
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03362060 |
Recruiting |
Massachusetts General Hospital |
2021-12-31 |
| NCT00813956 |
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT00813956 |
Completed |
Sanofi |
2012-10-31 |
| NCT03907800 |
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer |
https://ClinicalTrials.gov/show/NCT03907800 |
Recruiting |
Ruijin Hospital |
2022-10-31 |
| NCT03849469 |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03849469 |
Recruiting |
Xencor, Inc. |
2026-09-30 |
| NCT03544125 |
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03544125 |
Active, not recruiting |
OHSU Knight Cancer Institute |
2018-08-07 |
| NCT03164993 |
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT03164993 |
Recruiting |
Oslo University Hospital |
2021-08-01 |
| NCT03075462 |
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT03075462 |
Active, not recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2019-12-31 |
| NCT02819518 |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) |
https://ClinicalTrials.gov/show/NCT02819518 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2019-12-30 |
| NCT02583542 |
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT02583542 |
Active, not recruiting |
Queen Mary University of London |
2020-03-31 |
| NCT02580448 |
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) |
https://ClinicalTrials.gov/show/NCT02580448 |
Completed |
Innocrin Pharmaceutical |
2019-01-31 |
| NCT02779855 |
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT02779855 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-08-31 |
| NCT02499367 |
Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients |
https://ClinicalTrials.gov/show/NCT02499367 |
Active, not recruiting |
The Netherlands Cancer Institute |
2020-08-31 |
| NCT03797326 |
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) |
https://ClinicalTrials.gov/show/NCT03797326 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2024-02-24 |
| NCT02404441 |
Phase I/II Study of PDR001 in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT02404441 |
Active, not recruiting |
Novartis |
2020-07-01 |
| NCT02555657 |
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) |
https://ClinicalTrials.gov/show/NCT02555657 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2019-04-11 |
| NCT00733408 |
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT00733408 |
Completed |
University of Washington |
2017-07-05 |
| NCT00707707 |
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer |
https://ClinicalTrials.gov/show/NCT00707707 |
Completed |
AstraZeneca |
2009-11-09 |
| NCT00371254 |
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-negative’ Breast Cancer |
https://ClinicalTrials.gov/show/NCT00371254 |
Completed |
Bristol-Myers Squibb |
2008-09-30 |
| NCT00031681 |
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
https://ClinicalTrials.gov/show/NCT00031681 |
Completed |
National Cancer Institute (NCI) |
2011-01-31 |